Program
Dolutegravir
Also written as “GSK1349572”, “DTG” and “Dolutegravir 50 mg”.
Its studies are mostly in Infections · HIV Infections · Malaria · Acquired Immunodeficiency Syndrome · Tuberculosis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 643 open or running | phase 4since Oct 13, 2017 | Nov 5, 2007 | Sep 14, 2032phase 3 · NCT07393659 |
| Humanis Saglık Anonim Sirketi | 10 open or running | phase 1since Jun 4, 2024 | Jun 4, 2024 | none ahead |
| Viatris | 10 open or running | early phase 1since Jul 28, 2021 | Jul 28, 2021 | none ahead |
Also a collaborator on its studies: ppd-development-lp, Johnson & Johnson and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Jan 22, 2009.
- Oct 13, 2017Phase 4 study in InfectionsGlaxoSmithKline · NCT03314064 · 43 enrolled · Russian Federation
- Jan 5, 2018Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03446573 · 743 enrolled · United States, Australia, Belgium and more
- Sep 21, 2018Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03682848 · 32 enrolled · Kenya, South Africa, Thailand
- Jan 22, 2019Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT03816696 · 16 enrolled · United States
- Apr 17, 2019Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT03921723 · 22 enrolled · United Kingdom
- May 8, 2019Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03945981 · 131 enrolled · United States
- Jul 11, 2019Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT04021290 · 493 enrolled · United States, Argentina, Belgium and more
- Apr 28, 2021Phase 2 study in HIV InfectionsGlaxoSmithKline · NCT04871113 · 62 enrolled · United States, Argentina, Brazil and more
- Jul 28, 2021Viatris's first study: early phase 1 study in HIV-1-infectionNew to ViatrisViatris · NCT05030025 · 43 enrolled · Canada
- Dec 7, 2022Phase 2 study in HIV InfectionsGlaxoSmithKline · NCT05674656 · 20 planned · United States
- Jun 9, 20232 phase 3 studies in HIV InfectionsGlaxoSmithKline · NCT05911360, NCT05917509
- Jul 19, 2023Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT05979311 · 463 enrolled · Argentina, Belgium, Denmark and more
- Jun 4, 2024Humanis Saglık Anonim Sirketi's first study: phase 1 study in HIV InfectionsNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06450275 · 32 enrolled · Jordan
- Jan 30, 2026Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT07393659 · 197 planned · Romania, South Africa, Uganda
Ahead
- Sep 14, 2032Primary completion: phase 3 study in HIV InfectionsGlaxoSmithKline · NCT07393659
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 integrase inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 66 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07393659HIV Infections · Romania, South Africa, Uganda | 3 | Recruiting | GlaxoSmithKline | Sep 14, 2032 | 197 |
| NCT06450275HIV Infections · Jordan | 1 | Completed | Humanis Saglık Anonim Sirketi | Jan 15, 2024 | 32 |
| NCT05979311HIV Infections · Argentina, Belgium, Denmark and more | 3 | Active, not recruiting | GlaxoSmithKline | Apr 15, 2026 | 463 |
| NCT05917509HIV Infections · United States, Argentina, Canada and more | 3 | Completed | GlaxoSmithKline | Sep 16, 2025 | 171 |
| NCT05911360HIV Infections · United States, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | Jan 23, 2026 | 205 |
| NCT05674656HIV Infections · United States | 2 | Recruiting | GlaxoSmithKline | Jun 1, 2026 | 20 |
| NCT05030025HIV-1-infection · Canada | Early 1 | Completed | Viatris | Aug 29, 2021 | 43 |
| NCT04871113HIV Infections · United States, Argentina, Brazil and more | 2 | Completed | GlaxoSmithKline | Oct 27, 2022 | 62 |
| NCT04021290HIV Infections · United States, Argentina, Belgium and more | 3 | Completed | GlaxoSmithKline | Apr 23, 2021 | 493 |
| NCT03945981HIV Infections · United States | 3 | Completed | GlaxoSmithKline | Apr 29, 2020 | 131 |
| NCT03921723HIV Infections · United Kingdom | 1 | Completed | GlaxoSmithKline | Jul 25, 2019 | 22 |
| NCT03816696HIV Infections · United States | 1 | Completed | GlaxoSmithKline | Mar 30, 2019 | 16 |
| NCT03682848HIV Infections · Kenya, South Africa, Thailand | 3 | Completed | GlaxoSmithKline | Dec 1, 2021 | 32 |
| NCT03446573HIV Infections · United States, Australia, Belgium and more | 3 | Completed | GlaxoSmithKline | May 20, 2019 | 743 |
| NCT03314064Infections · Russian Federation | 4 | Completed | GlaxoSmithKline | Oct 1, 2018 | 43 |
| NCT03078556Infections · United States | 1 | Completed | GlaxoSmithKline | Aug 18, 2017 | 154 |
| NCT03016533HIV Infections · United States, Botswana, Brazil and more | 3 | Completed | GlaxoSmithKline | Dec 24, 2024 | 100 |
| NCT02893488Infections · United States | 1 | Completed | GlaxoSmithKline | Nov 1, 2016 | 20 |
| NCT02741557Infections · United States | 1 | Completed | GlaxoSmithKline | Oct 24, 2016 | 118 |
| NCT02738931Infections · United States | 1 | Completed | GlaxoSmithKline | Jun 2016 | 30 |
| NCT02715479Infections · United States | 1 | Completed | GlaxoSmithKline | May 2016 | 14 |
| NCT02227238HIV Infections · Argentina, Brazil, Chile and more | 3 | Completed | GlaxoSmithKline | Aug 2, 2017 | 627 |
| NCT02185300Infections · United States | 1 | Completed | GlaxoSmithKline | Sep 2014 | 15 |
| NCT02178592Infections · Argentina, Brazil, Mexico and more | 3 | Completed | GlaxoSmithKline | Nov 2, 2017 | 113 |
| NCT02105987Infections · United States, Canada, Puerto Rico | 3 | Completed | GlaxoSmithKline | Apr 2015 | 555 |
| NCT02082808Infections · United States | 1 | Completed | GlaxoSmithKline | May 2014 | 12 |
| NCT02075593Infections · Russian Federation, Spain | 3 | Completed | GlaxoSmithKline | Oct 22, 2018 | 4 |
| NCT02064374Infections · United States | 1 | Completed | GlaxoSmithKline | May 2014 | 30 |
| NCT01967771Infections · United States | 1 | Completed | GlaxoSmithKline | Jan 2014 | 16 |
| NCT01910402Infections · United States, Argentina, Canada and more | 3 | Completed | GlaxoSmithKline | Sep 22, 2015 | 499 |
| NCT01622790Infections · United States | 1 | Completed | GlaxoSmithKline | Aug 2012 | 66 |
| NCT01568892HIV Infections · United States | 3 | Completed | GlaxoSmithKline | Oct 31, 2012 | 30 |
| NCT01536873Infections · United States, Austria, Belgium and more | – | Completed | GlaxoSmithKline | Sep 23, 2016 | 200 |
| NCT01498861Infections · United States | 1 | Completed | GlaxoSmithKline | Mar 2012 | 16 |
| NCT01499199Infections · United States | 3 | Completed | GlaxoSmithKline | Oct 2012 | 13 |
| NCT01467531Infections · United States | 1 | Completed | GlaxoSmithKline | Feb 2012 | 28 |
| NCT01467518Infections · Canada | 1 | Completed | GlaxoSmithKline | Feb 2012 | 11 |
| NCT01449929Infections · United States, France, Germany and more | 3 | Completed | GlaxoSmithKline | Apr 22, 2013 | 488 |
| NCT01425099Infections · United States | 1 | Completed | GlaxoSmithKline | Oct 2011 | 12 |
| NCT01382238Infections · United States | 1 | Completed | GlaxoSmithKline | Aug 2011 | 20 |
| NCT01366547Infections · United States | 1 | Completed | GlaxoSmithKline | Jul 2011 | 18 |
| NCT01353716Infections · United States | 1 | Completed | GlaxoSmithKline | Apr 2012 | 16 |
| NCT01332565Infections · United States | 1 | Completed | GlaxoSmithKline | Jun 2011 | 10 |
| NCT01328041Infections · United States, Belgium, Canada and more | 3 | Completed | GlaxoSmithKline | May 2012 | 183 |
| NCT01283100Infections · United States | 1 | Withdrawn | GlaxoSmithKline | Mar 2011 | 0 |
| NCT01231516Infections · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Feb 4, 2013 | 724 |
| NCT01231529Infections · United States | 1 | Completed | GlaxoSmithKline | Jun 4, 2011 | 16 |
| NCT01227824Infections · United States, Australia, Canada and more | 3 | Completed | GlaxoSmithKline | Feb 6, 2012 | 828 |
| NCT01214993Infections · United States | 1 | Completed | GlaxoSmithKline | Nov 2010 | 38 |
| NCT01209065Infections · United States | 1 | Completed | GlaxoSmithKline | Nov 2010 | 27 |
| NCT01098513Infections · United States | 1 | Completed | GlaxoSmithKline | Jun 2010 | 24 |
| NCT01098526Infections · United States | 1 | Completed | GlaxoSmithKline | May 26, 2010 | 12 |
| NCT01068925Infections · United States | 1 | Completed | GlaxoSmithKline | Apr 5, 2010 | 18 |
| NCT00996021Healthy Subjects · United States | 1 | Completed | GlaxoSmithKline | Nov 2009 | 42 |
| NCT00951015Infections · United States, France, Germany and more | 2 | Completed | GlaxoSmithKline | Feb 26, 2010 | 208 |
| NCT00950859Infections · United States, Canada, France and more | 2 | Completed | GlaxoSmithKline | Nov 2010 | 51 |
| NCT00942136HIV Infections · United States | 1 | Completed | GlaxoSmithKline | Sep 2009 | 24 |
| NCT00883935Healthy Volunteer · United States | 1 | Completed | GlaxoSmithKline | Jun 2009 | 24 |
| NCT00867152Healthy Volunteer · United States | 1 | Completed | GlaxoSmithKline | May 2009 | 17 |
| NCT00858455Healthy Volunteer · United States | 1 | Completed | GlaxoSmithKline | Mar 2009 | 16 |
How it is read
Names in the registry
- “GSK1349572”, 20 entries
- “Dolutegravir”, 12 entries
- “DTG”, 6 entries
- “Dolutegravir 50 mg”, 4 entries
- “DTG/3TC”, 2 entries
Conditions, from the studies’ own filings
- Infections, 31 studies
- HIV Infections, 25 studies
- Malaria, 1 study
- Acquired Immunodeficiency Syndrome, 1 study
- Tuberculosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.